

**Amendments to the Claims:**


Claims 1-2, 10 and 12 have been canceled and Claims 3-9, 11, 13, 14, and 18 have been amended herein. Please note that all the claims currently pending and under consideration in the referenced application are shown below, in clean form, for clarity. Please enter these claims as amended. Also attached is a version with markings to show changes made to the claims.

Please cancel Claims 1-2, 10 and 12 without prejudice or disclaimer.

Please amend Claims 3-9, 11, 13, 14, and 18 as follows:

3. (Amended ) An essentially pure compound having the following structure of


Formula II:



wherein R<sup>1</sup> is isobutyl (-CH<sub>2</sub>-CH(CH<sub>3</sub>)<sub>2</sub>).


4. (Amended ) A pharmaceutical composition comprising a therapeutically effective amount of the essentially pure compound as claimed in claim 3 together with at least one pharmaceutically acceptable excipient.
5. (Amended ) The pharmaceutical composition of claim 4, wherein the composition is in oral form.
6. (Amended ) The pharmaceutical composition of claim 4, wherein the composition is in intravenous form.

7. (Amended ) The pharmaceutical composition of claim 4, wherein the composition is in subcutaneous form.
8. (Amended ) The pharmaceutical composition of claim 4, wherein the composition is in intramuscular form.
9. (Amended ) The pharmaceutical composition of claim 4, wherein the composition is in inhalation form.
11. (Amended ) The pharmaceutical composition of claim 4, wherein said composition is chemically modified as a therapeutically effective salt.
13. (Amended ) A method of obtaining an essentially pure compound of Formula II:




wherein R<sup>1</sup> is isobutyl (-CH<sub>2</sub>-CH(CH<sub>3</sub>)<sub>2</sub>), comprising extracting and purifying the compound from *Piper laetispicum* of Piperaceae family.

14. (Amended ) A method of treating a disease characterized as mental disorder, comprising administering to a patient suffering from said disease with a therapeutically effective amount of an essentially pure compound of Formula I:



wherein  $R^1$  is selected from the group consisting of hydrogen,  $C_{1-10}$  alkyl and aromatic cyclic group,  $R^2$  is selected from the group consisting of hydrogen,  $OR^3$ ,  $NH_2$ ,  $NHR^3$ , and halogen, Z is selected from the group consisting of  $=O$ ,  $OH$ ,  $NHR^3$ ,  $SH$ , and  $SR^3$ , wherein  $R^3$  is  $C_{1-10}$  alkyl or aromatic cyclic group,  $(C_7-C_8)_n$  includes at least one single bond or at least one double bond,  $n$  is an integer having a value of 0 to 10, and Y is selected from the group consisting of  $NH$ ,  $NR^3$ , O, and S.

15. The method of claim 14, wherein the disease is depression.
16. The method of claim 14, wherein the disease is psychopathic disease.
17. The method of claim 14, wherein the disease is Alzheimer's disease.
18. (Amended ) A method of alleviating a symptom characterized as inflammation and pain, comprising administering to a subject suffering from said symptom with a therapeutically effective amount of an essentially pure compound of Formula I:



wherein  $R^1$  is selected from the group consisting of hydrogen,  $C_{1-10}$  alkyl and aromatic cyclic group,  $R^2$  is selected from the group consisting of hydrogen,  $OR^3$ ,  $NH_2$ ,  $NHR^3$ , and halogen, Z is selected from the group consisting of  $=O$ ,  $OH$ ,  $NHR^3$ ,  $SH$ , and  $SR^3$ , wherein  $R^3$  is  $C_{1-10}$  alkyl or aromatic cyclic group,  $(C_7-C_8)_n$  includes at least one single bond or at least one double bond,  $n$  is an integer having a value of 0 to 10, and Y is selected from the group consisting of  $NH$ ,  $NR^3$ , O, and S.